hVIVO plc HVO
LSE · United Kingdom · Commercial Services
GBp 6.20+0.10 (+1.64%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Sunda Energy PLC (AIM:SNDA, FRA:GHA0) has raised £5.25 million to fund completion of its New Zealand acquisition. It's also launching a retail offer for a further £525,000. Meridian Mining Plc (LSE:MNO, TSX:MNO, OTCQX:MRRDF) has delivered a net present value of $2.09 billion for its Cabaçal project in Brazil. The CEO says the economics could make it the next major near-term gold-copper mine. Quantum Helium Ltd (AIM:QHE) is targeting Q4 2026 for a larger fracture stimulation programme at Sagebrush-1 in Colorado. It's also taking a 9% stake in Herencia Resources. Light Science Technologies Holdi
Pan African Resources PLC (LSE:PAF, OTCQX:PAFRY, JSE:PAN) has reported record production and earnings for FY2026 after a 40% jump in output. It's now moved from net debt to a "really healthy cash balance." CEO Cobus Loots says its 2027 production target is not a massive stretch. Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) has delivered a sixth straight year of growth, with profit up 24%. CFO Kris Hampson says the group is well positioned, with a very healthy order book. IP Group PLC (LSE:IPO) has made a strong start to 2026, with NAV per share reaching around 117p. Cash proceeds have alread
hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan spoke with Proactive's Stephen Gunnion about the company's results for the first half of 2026, its record order book, full-year guidance and the expansion of its clinical research services. Khan said hVIVO generated around £16.3 million in revenue in H1, alongside an EBITDA loss of £4.5 million, ending the period with £13 million in cash, a performance in line with the company's previous guidance that 2026 would be weighted towards the second half. A key focus was the order book. Three sizeable human challenge trial contracts, including hVIVO
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.